Royalty Pharma plc

General Information
Business:

 

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi. 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 0
Founded: 1996
Contact Information
Address 110 East 59th Street, New York, NY 10022, US
Phone Number (212) 883-0200
Web Address http://www.royaltypharma.com
View Prospectus: Royalty Pharma plc
Financial Information
Market Cap $16670.7mil
Revenues $1880.25 mil (last 12 months)
Net Income $2052.3 mil (last 12 months)
IPO Profile
Symbol RPRX
Exchange NASDAQ
Shares (millions): 77.7
Price range $28.00 - $28.00
Est. $ Volume $2175.1 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ BofA Securities/ Goldman Sachs/ Citigroup/ UBS Investment Bank
CO-Managers Evercore ISI/ Cowen/ SunTrust Robinson Humphrey/ BBVA/ DNB Markets/ Scotiabank/ TD Securities Academy Securities/ AmeriVet Securities/ Blaylock Van/ Cabrera Capital Markets/ R. Seelaus/ Ramirez/ Siebert Williams Shank/ Tigress Financial Partners
Expected To Trade: 6/16/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change